Ligand Pharmaceuticals Incorporated EPS (Earnings per Share) 2009–2025
Ligand Pharmaceuticals Incorporated reported $6.13 of earnings per share for fiscal 2025. That was 2886.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +3505.6%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $6.13 | +2886.4% |
| FY 2024 | $-0.22 | -107.5% |
| FY 2023 | $2.94 | +248.5% |
| FY 2022 | $-1.98 | -159.8% |
| FY 2021 | $3.31 | +1938.9% |
| FY 2020 | $-0.18 | -100.6% |
| FY 2019 | $31.85 | +434.4% |
| FY 2018 | $5.96 | +1024.5% |
| FY 2017 | $0.53 | +762.5% |
| FY 2016 | $-0.08 | -100.7% |
| FY 2015 | $10.83 | +1833.9% |
| FY 2014 | $0.56 | +1.8% |
| FY 2013 | $0.55 | +1933.3% |
| FY 2012 | $-0.03 | -106.1% |
| FY 2011 | $0.49 | — |
| FY 2010 | $0.00 | — |
| FY 2009 | $0.00 | — |
Source: Ligand Pharmaceuticals Incorporated SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open LGND 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Ligand Pharmaceuticals Incorporated reported $6.13 of earnings per share for fiscal 2025. That was 2886.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +3505.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Ligand Pharmaceuticals Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeLigand Pharmaceuticals Incorporated — frequently asked questions
What is Ligand Pharmaceuticals Incorporated's earnings per share?
Ligand Pharmaceuticals Incorporated (LGND) reported earnings per share of $6.13 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Ligand Pharmaceuticals Incorporated's official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.